ProCE Banner Activity

Slideset: Pharmacotherapy of Schizophrenia

Slideset Download

This presentation on pharmacotherapy of schizophrenia will review the role of shared decision-making, considerations in balancing efficacy and tolerability, the role of maintenance treatment, whether long-acting formulations help in reducing relapse risk, and when clozapine is indicated.

Released: December 08, 2021

Share

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by educational grants from

Intra Cellular Therapies

Faculty Disclosure

Primary Author

John M. Kane, MD

Co-Director, Institute of Behavioral Science
Feinstein Institutes for Medical Research
Professor, Psychiatry and Molecular Medicine
Donald and Barbara Zucker School of Medicine at Hofstra/Northwell
New York, New York

John M. Kane, MD, has disclosed that he has received funds for research support from H. Lundbeck, Janssen, and Otsuka; has received consulting fees from Alkermes, Allergan, Dainippon Sumitomo, H. Lundbeck, Intra-Cellular Therapies, Janssen, LB Pharmaceuticals, Lyndra, Merck, Neurocrine Biosciences, Otsuka, Reviva, Roche, Saladex, Sunovion, Takeda, and Teva; has ownership interest in LB Pharmaceuticals, Merck, Minerva, and North Shore Therapeutics; and has received fees for non-CME/CE services from Dainippon Sumitomo, H. Lundbeck, Janssen, and Otsuka.